Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M; NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society. Wick W, et al. Lancet Oncol. 2012 Jul;13(7):707-15. doi: 10.1016/S1470-2045(12)70164-X. Epub 2012 May 10. Lancet Oncol. 2012. PMID: 22578793 Free article. Clinical Trial.
Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma.
Wick A, Kessler T, Platten M, Meisner C, Bamberg M, Herrlinger U, Felsberg J, Weyerbrock A, Papsdorf K, Steinbach JP, Sabel M, Vesper J, Debus J, Meixensberger J, Ketter R, Hertler C, Mayer-Steinacker R, Weisang S, Bölting H, Reuss D, Reifenberger G, Sahm F, von Deimling A, Weller M, Wick W. Wick A, et al. Neuro Oncol. 2020 Aug 17;22(8):1162-1172. doi: 10.1093/neuonc/noaa033. Neuro Oncol. 2020. PMID: 32064499 Free PMC article.
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide.
Dresemann G, Weller M, Rosenthal MA, Wedding U, Wagner W, Engel E, Heinrich B, Mayer-Steinacker R, Karup-Hansen A, Fluge O, Nowak A, Mehdorn M, Schleyer E, Krex D, Olver IN, Steinbach JP, Hosius C, Sieder C, Sorenson G, Parker R, Nikolova Z. Dresemann G, et al. J Neurooncol. 2010 Feb;96(3):393-402. doi: 10.1007/s11060-009-9976-3. Epub 2009 Aug 18. J Neurooncol. 2010. PMID: 19688297 Clinical Trial.
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.
Herrlinger U, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Maciaczyk J, Grau S, Schnell O, Hänel M, Krex D, Vajkoczy P, Gerlach R, Kortmann RD, Mehdorn M, Tüttenberg J, Mayer-Steinacker R, Fietkau R, Brehmer S, Mack F, Stuplich M, Kebir S, Kohnen R, Dunkl E, Leutgeb B, Proescholdt M, Pietsch T, Urbach H, Belka C, Stummer W, Glas M. Herrlinger U, et al. J Clin Oncol. 2016 May 10;34(14):1611-9. doi: 10.1200/JCO.2015.63.4691. Epub 2016 Mar 14. J Clin Oncol. 2016. PMID: 26976423 Clinical Trial.
Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07).
Beier D, Proescholdt M, Reinert C, Pietsch T, Jones DTW, Pfister SM, Hattingen E, Seidel C, Dirven L, Luerding R, Reijneveld J, Warmuth-Metz M, Bonsanto M, Bremer M, Combs SE, Rieken S, Herrlinger U, Kuntze H, Mayer-Steinacker R, Moskopp D, Schneider T, Beringer A, Schlegel U, Stummer W, Welker H, Weyerbrock A, Paulsen F, Rutkowski S, Weller M, Wick W, Kortmann RD, Bogdahn U, Hau P. Beier D, et al. Neuro Oncol. 2018 Feb 19;20(3):400-410. doi: 10.1093/neuonc/nox155. Neuro Oncol. 2018. PMID: 29016837 Free PMC article. Clinical Trial.
Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study.
Dirven L, Luerding R, Beier D, Bumes E, Reinert C, Seidel C, Bonsanto MM, Bremer M, Rieken S, Combs SE, Herrlinger U, Seliger C, Kuntze H, Mayer-Steinacker R, Dieing A, Bartels C, Schnell O, Weyerbrock A, Seidel S, Grauer O, Nadji-Ohl M, Paulsen F, Weller M, Wick W, Hau P. Dirven L, et al. Among authors: mayer steinacker r. J Neurooncol. 2020 May;148(1):117-130. doi: 10.1007/s11060-020-03502-y. Epub 2020 May 4. J Neurooncol. 2020. PMID: 32367436 Free PMC article.
Rare phenomenon: liver metastases from glioblastoma multiforme.
Schönsteiner SS, Bommer M, Haenle MM, Klaus B, Scheuerle A, Schmid M, Mayer-Steinacker R. Schönsteiner SS, et al. J Clin Oncol. 2011 Aug 10;29(23):e668-71. doi: 10.1200/JCO.2011.35.9232. Epub 2011 Jun 13. J Clin Oncol. 2011. PMID: 21670450 No abstract available.
Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial.
Schmoll HJ, Lindner LH, Reichardt P, Heißner K, Kopp HG, Kessler T, Mayer-Steinacker R, Rüssel J, Egerer G, Crysandt M, Kasper B, Niederwieser D, Kunitz A, Eigendorff E, Petersen I, Steighardt J, Cygon F, Meinert F, Stein A. Schmoll HJ, et al. Among authors: mayer steinacker r. JAMA Oncol. 2021 Feb 1;7(2):255-262. doi: 10.1001/jamaoncol.2020.6564. JAMA Oncol. 2021. PMID: 33355646 Free PMC article. Clinical Trial.
Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
Hartmann JT, Gauler T, Metzner B, Gerl A, Casper J, Rick O, Horger M, Schleicher J, Derigs G, Mayer-Steinacker R, Beyer J, Kuczyk MA, Bokemeyer C; German Testicular Cancer Study Group. Hartmann JT, et al. J Clin Oncol. 2007 Dec 20;25(36):5742-7. doi: 10.1200/JCO.2007.11.9099. J Clin Oncol. 2007. PMID: 18089869 Clinical Trial.
A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3.
Halatsch ME, Kast RE, Karpel-Massler G, Mayer B, Zolk O, Schmitz B, Scheuerle A, Maier L, Bullinger L, Mayer-Steinacker R, Schmidt C, Zeiler K, Elshaer Z, Panther P, Schmelzle B, Hallmen A, Dwucet A, Siegelin MD, Westhoff MA, Beckers K, Bouche G, Heiland T. Halatsch ME, et al. Among authors: mayer steinacker r. Neurooncol Adv. 2021 Jun 24;3(1):vdab075. doi: 10.1093/noajnl/vdab075. eCollection 2021 Jan-Dec. Neurooncol Adv. 2021. PMID: 34377985 Free PMC article.
44 results